Abstract:In this study, six N-1, N-2, or N-11 derivatives of TD-34 (a cationic cyclic cell-penetrating peptide [CPP], ACSSKKSKHCG) were designed and synthesized including both linear peptides and cyclic peptides, such as DL-1 (KWSSKKSKHCG), DLCC-1 (cyclopeptide, KWSSKKSKHCG), DL-2 (KWSSKKSKHCG-NH2 ), DLCC-2 (cyclopeptide, KWSSKKSKHCG-NH2 ), DL-3 (RWSSKKSKHCG), and DLCC-3 (cyclopeptide, RWSSKKSKHCG). The cyclic peptides were synthesized by disulfide bound linkages formed by N-2 and N-10 cysteine. In vitro penetration experiment was conducted to investigate the transdermal enhancement ability of these derivatives, using triptolide (TP) as model drug. The results display that at the presence of DLCC-2, the accumulative penetration amount of TP increased 1.71-fold (P < .05) within 12 hours, displaying better transdermal enhancing ability than TD-34. Meanwhile, DL-3 and DLCC-3 slightly decreased the transdermal delivery of TP, and the presence of DL-1 and DLCC-1 shows no obvious effect. In order to clarify the factors on the transdermal ability of peptides, the solubility of TP in phosphate buffer saline (PBS) at the presence of different peptides and the mechanism of transdermal delivery of CPPs was investigated. The result shows that most of these peptides have no significant effect on the solubility of TP except DLCC-3 (the solubility of TP slightly increased). And in order to investigate transdermal absorption route of DLCC-2, polyarginine linked to rhodamine b (Rh b) derivative is used. The result proved that the transdermal route of polyarginine is via hair follicle, which may change the transdermal route of its cargo molecule (TP). Our group previously proved that polyarginine and TD-34 have similar transdermal enhancing mechanism (changing the transdermal route of their cargo molecule); it is reasonably speculated that the transdermal route of DLCC-2 is the same as polyarginine and then changes the transdermal absorption route of TP. Furthermore, such results have laid a solid foundation for further investigation of CPPs and paved a way for both designing and synthesizing of new drug delivery system for therapy molecules.

Transdermal delivery of fusion green fluorescent protein mediated by covalently associated TD1 peptide

[A Study on Transfection of Green Fluorescence Protein Gene into Human Adipose Stromal Cells in Vitro].

Enhanced Transdermal Delivery of Epidermal Growth Factor Facilitated by Dual Peptide Chaperone Motifs

Transdermal Delivery of Human Epidermal Growth Factor Facilitated by A Peptide Chaperon

Intracellular Delivery of Native Proteins Facilitated by Cell-Penetrating Poly(disulfide)s.

Genetic Fusion of Transacting Activator of Transcription Peptide to Cyclized Green Fluorescence Protein Improves Stability, Intracellular Delivery, and Tumor Retention

Peptide-chaperone-directed Transdermal Protein Delivery Requires Energy.

Improved transfer efficiency of supercharged 36 + GFP protein mediate nucleic acid delivery

Improved efficacy of linear glutathione-peptide chaperon complexes on melanogenesis inhibition and transdermal delivery

Fusion with Pep-1, a Cell-Penetrating Peptide, Enhances the Transmembrane Ability of Human Epidermal Growth Factor

Genetically engineered epidermal growth factor conjugate crosses cell membrane

Transdermal protein delivery by a coadministered peptide identified via phage display

Synthesis, characterization, and evaluation of novel cell-penetrating peptides based on TD-34

Evaluating the translocation properties of a new nuclear targeted penetrating peptide using two fluorescent markers.

Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis

Nature-inspired peptide of MtDef4 C-terminus tail enables protein delivery in mammalian cells

Recent Advances in Peptides for Enhancing Transdermal Macromolecular Drug Delivery.

A Novel Recombinant Protein Tat-Gfp-Kdel with Dual-Function of Penetrating Cell Membrane and Locating at Endoplasm Reticulum

Tetraphenylethylene-Featured Fluorescent Supramolecular Nanoparticles for Intracellular Trafficking of Protein Delivery and Neuroprotection

Application of EGF-like Growth Factor-derived Tumor-homing Peptide for Antineoplastic Protein

Application of EGFP-EGF fusions to explore mechanism of endocytosis of epidermal growth factor